Due to a measles case in the community, please call before coming to Seattle Children’s if you or your child has potential measles symptoms.

Current Research Studies

TReatment for ImmUne Mediated PathopHysiology

TRIUMPH

Phase: II
Clinicaltrials.gov ID: NCT04862221

What is the goal of the study?

This is a phase 2b, double-blind, tree arm, randomized, placebo controlled trial with restricted response adaptive randomization. The trial is designed to test the efficacy and safety of high dose methylprednisolone or equine anti-thymocyte globulin (eATG) as compared to supportive care alone for the treatment of acute liver failure in pediatric patients. The primary outcome will be survival with native liver at 21 days following study entry.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Pamela Valentino
Study Team Member: Chelsea Caranto, Chelsea.Caranto@seattlechildrens.org

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.